| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
| Company Name: |
Cckinase, Inc. |
| Tel: |
+1 (732)236-3202 |
| Email: |
sales@cckinase.com |
- AX-024
-
- $67.00
-
2026-05-11
- CAS:1370544-73-2
- Purity:
- Supply Ability: 10g
|
| | AX-024 hcl Basic information |
| Product Name: | AX-024 hcl | | Synonyms: | AX-024 hcl;AX 024;AX024;CS-2619;Pyrrolidine, 1-[[4-(4-fluorophenyl)-6-methoxy-2H-1-benzopyran-3-yl]methyl]-;1-((4-(4-FLUOROPHENYL)-6-METHOXY-2H-CHROMEN-3-YL)METHYL)PYRROLIDINE | | CAS: | 1370544-73-2 | | MF: | C21H22FNO2 | | MW: | 339.4 | | EINECS: | | | Product Categories: | | | Mol File: | 1370544-73-2.mol |  |
| | AX-024 hcl Chemical Properties |
| Boiling point | 452.0±45.0 °C(Predicted) | | density | 1.201±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:35.0(Max Conc. mg/mL);103.12(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);294.63(Max Conc. mM) | | pka | 9.26±0.20(Predicted) | | form | Solid | | color | Light yellow to yellow |
| | AX-024 hcl Usage And Synthesis |
| Description | AX-024 is an inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation. AX-024 modulates cell signaling by targeting SH3 domains and has low-acute toxicity and high potency and selectivity in the inhibition of the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A. | | Uses | AX-024, is >10,000-fold more potent than the AX-000 hit in terms of inhibition of TCR-triggered T cell proliferation. It is a cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A. | | in vitro | AX-024 reduces T cell proliferation upon weak T cell receptor (TCR) stimulation but neither significantly affects phosphorylation of Zap70 (ζ chain of T cell receptor–associated protein kinase 70) nor interacts directly with Nck1-SH3. AX-024 is likely not involved in modulating the Nck/TCR interaction but probably has other targets in T cells. An array of biophysical techniques did not detect a direct interaction between AX-024 and Nck-SH3.1 in vitro._x000D_
_x000D_
Reference: J Biol Chem. 2020 Jun 5;295(23):7849-7864. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7278359/#B11 | | in vivo | AX-024-treated group presents less scales and reduces skin thickening compare to the vehicle group. AX-024 significantly reduces thickening of both skin layers, but more effectively of the dermis, which rather resembles that of mice treated with a control cream lacking imiquimod (IMQ). AX-024 significantly diminishes the number of airway inflammatory cells in both assays. Mice receiving AX-024 rapidly recovers from neurological impairment and weight loss, becoming symptom-free by day 30, unlike mice that receives the vehicle, in which ataxia and loss of the righting reflex persist[1]. | | target | AX-024 is an inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. | | IC 50 | IL-6; IL-10; IL-17A |
| | AX-024 hcl Preparation Products And Raw materials |
|